HC Wainwright Analysts Give Trillium Therapeutics Inc. (TRIL) a $7.00 Price Target
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) has been given a $7.00 price target by stock analysts at HC Wainwright in a research report issued on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 60.92% from the company’s current price.
Several other research analysts have also recently weighed in on TRIL. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $18.00 price objective on shares of Trillium Therapeutics in a research report on Friday, June 9th. Cowen and Company restated a “buy” rating on shares of Trillium Therapeutics in a research note on Wednesday, July 5th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $14.95.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 4.35 on Monday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $17.70. The company’s market cap is $34.13 million. The company has a 50-day moving average price of $4.58 and a 200-day moving average price of $5.48.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Analysts Give Trillium Therapeutics Inc. (TRIL) a $7.00 Price Target” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/14/hc-wainwright-analysts-give-trillium-therapeutics-inc-tril-a-7-00-price-target.html.
Hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP bought a new stake in Trillium Therapeutics during the third quarter worth about $6,120,000. Susquehanna International Group LLP bought a new stake in Trillium Therapeutics during the third quarter worth about $372,000. Polar Capital LLP bought a new stake in Trillium Therapeutics during the third quarter worth about $488,000. Wells Fargo & Company MN raised its stake in Trillium Therapeutics by 1,080.0% in the third quarter. Wells Fargo & Company MN now owns 11,800 shares of the biotechnology company’s stock worth $175,000 after buying an additional 10,800 shares during the last quarter. Finally, Private Capital Advisors Inc. bought a new stake in Trillium Therapeutics during the third quarter worth about $2,167,000. Institutional investors own 45.94% of the company’s stock.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.